Wide-Ranging 21st Century Cures Act Signed into Law

On December 13, 2016, 38 days before leaving office, President Obama signed into law the 21st Century Cures Act.\(^1\) The law, considered by legal experts to be the “most comprehensive healthcare legislation to be enacted since the Patient Protection and Affordable Care Act [ACA] of 2010,”\(^2\) covers a wide variety of topics related to healthcare delivery, administration, and research, including:

1. Mental Health Treatment;
2. Biomedical Research;
3. Opioid Addiction Treatment;
4. Billing for Off-Campus Hospital Outpatient Departments (HOPDs);
5. ACA Health Insurance Exchanges; and,
6. The Hospital Readmissions Reduction Program (HRRP).\(^3\)

The law is expected to impact providers in a multitude of ways, including the delivery of mental health services and modifications to certain quality programs and site-of-service requirements. However, the ultimate effect of the law on healthcare delivery is still unclear, as Congress delegated implementation of numerous aspects of the law to various federal agencies. This Health Capital Topics article will summarize the important provisions of the 21st Century Cures Act as it relates to healthcare providers and discuss the potential benefits, as well as stated criticisms, of the legislation.

The 21st Century Cures Act contains numerous provisions related to the treatment of mental health and substance abuse problems (in particular, opioid addiction), including:

1. Section 14003, which requires the U.S. Department of Justice to establish a pilot program to test the effectiveness of mental health and drug courts to divert persons with mental illness and substance abuse disorders from prison;\(^4\)
2. Section 6001, which creates the office of the “Assistant Secretary for Mental Health and Substance Use,” which reports to the Secretary of the U.S. Department of Health and Human Services (HHS), to oversee mental health and substance abuse response efforts in HHS;\(^5\)
3. Sections 13001 and 13002, which seek to strengthen mental health parity laws by mandating the creation of guidance to develop compliance programs detecting violations of federal law relating to mental health, as well as requiring the development of an “action plan” among federal agencies tasked with enforcing mental health parity laws;\(^6\)
4. Section 9003, which creates a grant program to provide funding that promotes the development of integrated care models between primary care providers and behavioral health providers;\(^7\) and,
5. Sections 8001-8004, which create block grant programs targeted at providers of mental health and substance abuse treatment.\(^8\)

Additionally, the law earmarks $1 billion to be distributed to states over a two-year period to combat opioid abuse.\(^9\) The law contains a non-exhaustive list of acceptable uses of grant money for opioid addiction treatment, including prescription drug monitoring, development of addiction prevention programs, and training for healthcare providers to identify opioid abuse and safely prescribe opioids to patients.\(^10\)

In addition to provisions targeting the treatment of mental health and substance abuse disorders, the 21st Century Cures Act includes provisions related to the funding of biomedical research, as well as the approval of drugs, devices, and therapies stemming from such research. The law earmarks approximately $4.8 billion of research funding for the National Institutes of Health,\(^11\) which funding is subdivided into a variety of projects, e.g.:

1. Cancer Research – $1.8 billion;\(^12\)
2. Neurological Disease Research – approximately $1.5 billion; and,\(^13\)
3. Precision Medicine – approximately $1.4 billion.\(^14\)

Additionally, the law provides new avenues for medical device approval by the U.S. Food and Drug Administration (FDA). In particular, Section 3501 of the law provides for the creation of an expedited approval process by the FDA for “breakthrough devices.”\(^15\) Under the law, a “breakthrough device” is a medical device submitted for FDA approval:

1. “[T]hat provide[s] for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions; and,”
2. “[T]hat represent[s] breakthrough technologies:
   (a) “[F]or which no approved or cleared alternatives exist;”

(Continued on next page)
(b) “[T]hat offer significant advantages over existing approved or cleared alternatives, including the potential, compared to existing approved alternatives, to reduce or eliminate the need for hospitalization, improve patient quality of life, facilitate patients’ ability to manage their own care (such as through self-directed personal assistance), or establish long-term clinical efficiencies; or”

(c) “[T]he availability of which is in the best interest of patients.”[16] [Emphasis Added]

The law delegates to the FDA the responsibility of developing the exact timing and requirements of this streamlined approval process through the release of proposed and final regulations, with initial guidance to be released by December 2017.[17]

While the 21st Century Cures Act primarily targets biomedical research and the treatment of mental health and substance abuse disorders, the law also addresses areas within the healthcare delivery system that have been the subject of controversy in recent years. First, the law broadens the original exceptions to the prohibition against off-campus HOPDs billing under Medicare’s hospital outpatient prospective payment system (HOPPS) promulgated under the Bipartisan Budget Act of 2015. Originally, Section 603 of the Bipartisan Budget Act of 2015 prevented off-campus HOPDs that expected to begin billing Medicare after November 2, 2015, from utilizing the HOPPS as the primary form of facility reimbursement after December 31, 2016.[18] However, this law provided for two exceptions to the HOPPS billing prohibition:

1. HOPDs that qualified as a “Designated Emergency Department”;[19] or,
2. Grandfathered facilities, i.e., off-campus HOPDs receiving Medicare reimbursement under the HOPPS prior to December 2, 2015.[20]
(For a further discussion regarding these exceptions, please reference the December 2015 Health Capital Topics article, entitled, “Congress Changes Reimbursement Rules for Off-Campus Facilities.”[21])

The 21st Century Cures Act expands the exception related to grandfathered facilities under the Bipartisan Budget Act of 2015 in two forms. First, for calendar 2017, an off-campus HOPD fits within the grandfathering exception if HHS had received an attestation from the provider that the facility would operate as an off-campus HOPD – and therefore bill under the HOPPS – by December 2, 2015.[22] Second, for calendar years 2018 and beyond, an off-campus HOPD fits within the grandfathering exception if:

1. The provider submits an attestation to HHS within sixty (60) days after the passage of the 21st Century Cures Act (i.e., by mid-February 2017) that the HOPD meets the requirements to be considered an HOPD under the Medicare program;
2. The provider includes the HOPD on its Medicare enrollment form with HHS; and,
3. The subject HOPD was “mid-build” (i.e., the provider “had a binding written agreement with an outside unrelated party for the actual construction of [the HOPD]”) as of November 2, 2015.[23]

Additionally, the 21st Century Cures Act provides for a small but potentially significant modification to the tax treatment of health insurance coverage that may influence participation in the health insurance exchanges created under the ACA. Section 18001 of the 21st Century Cures Act makes it permissible for small businesses to subsidize the cost of out-of-pocket medical expenses and premiums that are incurred by their employees without incurring a tax burden with the Internal Revenue Service, starting in 2017.[24] The provision, which was originally included in the Small Business Health Care Relief Act of 2015, but was ultimately consolidated into the final 21st Century Cures Act, is designed to encourage small businesses to provide financial support to their employees to obtain health insurance coverage through the use of health reimbursement accounts.[25] However, the provision may secondarily encourage participation in the ACA-established individual health insurance marketplaces. First, the law may provide a financial incentive that indirectly prompts consumers to enter the ACA-established marketplaces for individual health insurance products, as consumers may become less price-sensitive to the costs of health insurance in light of their employer’s contributions. Second, if the provision does increase the number of persons in the individual health insurance market, the risk pool within this sector may diversify, likely with healthier, less costly beneficiaries enrolling in this market, in comparison to many current participants who are less healthy, and therefore more expensive to insure.[26]

In another noteworthy provision, the 21st Century Cures Act modifies Medicare’s HRRP program to account for dual eligibles, i.e., patients that possess coverage under both the Medicare and Medicaid programs. HRRP, established under the ACA, is intended to reduce the number of unintended hospital readmissions for conditions such as acute myocardial infarction, heart failure, and pneumonia.[27] To accomplish this goal, the program reduces a hospital’s Medicare Severity Diagnosis Related Group payment rates based on a hospital’s ratio of expected readmissions to actual readmissions, with reductions of three (3) percent in fiscal year 2015 and beyond.[28] Critics of HRRP, including the American Hospital Association, noted that the program, as originally established, did not account for socioeconomic factors in the calculation of its penalties, which negatively impacted hospitals serving vulnerable populations such as dual eligibles.[29] The 21st Century Cures Act attempts to address this issue by creating an “adjustment factor” to account for dual eligibles when determining penalties under HRRP.[30] However, the overall impact of this change is yet uncertain, as the law delegates to HHS the responsibility to determine the

(Continued on next page)
The exact nature of the “adjustment factor,” which must be implemented by fiscal year 2019, is unknown. The law has been praised by pharmaceutical companies for increasing research funding and streamlining the approval process for certain drugs and medical devices. Further, hospital groups have applauded Congress for decreasing HRRP penalties for safety-net hospitals treating a disproportionate share of dual eligibles. However, patient safety groups have criticized the law’s provisions related to the streamlined drug and device approval process, arguing that loosening approval requirements for drugs and medical devices may negatively impact patient safety. Critics to the law, including members of Congress, have argued that the bill does not fund enough research into innovative medical treatments for rare and chronic diseases. Synthesizing these competing perspectives may be difficult currently, as the law assigns the task of implementing many of its provisions to various regulatory bodies. Providers should follow regulatory changes implementing the 21st Century Cures Act, as well as prepare to meet applicable deadlines set forth in the law, including those related to off-campus HOPDs.

4 Ibid. § 14003(b).
5 Ibid. § 6001(a).
6 Ibid. § 13001(a), 13002(a)(1).
7 Ibid. § 9003(a).
8 Ibid. § 8001-8004.
9 Ibid. §1003(b)(2)(A).
10 Ibid. §1003(c)(2).
11 Ibid. §1001(b)(2)(A).
12 Ibid.
13 Ibid.
14 Ibid.
15 Ibid. §3051(a).
16 Ibid.
17 Ibid.
19 Ibid.
20 Ibid.
23 Ibid.
24 Ibid. §18001.
32 Ibid.
Mr. Cimasi holds a Master in Health Administration from the University of Maryland, as well as several professional designations: Accredited Senior Appraiser (ASA – American Society of Appraisers); Fellow Royal Institution of Chartered Surveyors (FRICS – Royal Institution of Chartered Surveyors); Master Certified Business Appraiser (MCBA – Institute of Business Appraisers); Certified Valuation Analyst (CVA – National Association of Certified Valuators and Analysts); and, Certified Merger & Acquisition Advisor (CM&AA – Alliance of Merger & Acquisition Advisors). He has served as an expert witness on cases in numerous courts, and has provided testimony before federal and state legislative committees. He is a nationally known speaker on healthcare industry topics, and is the author of several books, the latest of which include: “The Adviser’s Guide to Healthcare – 2nd Edition” [2015 – AICPA]; “Healthcare Valuation: The Financial Appraisal of Enterprises, Assets, and Services” [2014 – John Wiley & Sons]; “Accountable Care Organizations: Value Metrics and Capital Formation” [2013 – Taylor & Francis, a division of CRC Press]; and, “The U.S. Healthcare Certificate of Need Sourcebook” [2005 - Beard Books].

Mr. Cimasi is the author of numerous additional chapters in anthologies; books, and legal treatises; published articles in peer reviewed and industry trade journals; research papers and case studies; and, is often quoted by healthcare industry press. In 2006, Mr. Cimasi was honored with the prestigious “Shannon Pratt Award in Business Valuation” conferred by the Institute of Business Appraisers. Mr. Cimasi serves on the Editorial Board of the Business Appraisals Practice of the Institute of Business Appraisers, of which he is a member of the College of Fellows. In 2011, he was named a Fellow of the Royal Institution of Chartered Surveyors (RICS). In 2016, Mr. Cimasi was named a “Pioneer of the Profession” as part of the recognition of the National Association of Certified Valuators and Analysts (NACVA) “Industry Titans” awards, which distinguishes those whom have had the greatest impact on the valuation profession.

Mr. Cimasi has over thirty years of experience in serving clients, with a professional focus on the financial and economic aspects of healthcare service sector entities including: valuation consulting and capital formation services; healthcare industry transactions including joint ventures, mergers, acquisitions, and divestitures; litigation support & expert testimony; and, certificate-of-need and other regulatory and policy planning consulting.

Todd A. Zigra, MBA, MHA, ASA, FACHE, is the President of Health Capital Consultants (HCC), where he focuses on the areas of valuation and financial analysis for hospitals, physician practices, and other healthcare enterprises. Mr. Zigra has over 20 years of experience providing valuation, financial, transactional and strategic advisory services nationwide in over 1,000 transactions and joint ventures. Mr. Zigra is also considered an expert in the field of healthcare compensation for physicians, executives and other professionals.

Mr. Zigra is the co-author of “The Adviser’s Guide to Healthcare – 2nd Edition” [2015 – AICPA], numerous chapters in legal treatises and anthologies, and peer-reviewed and industry articles such as: The Accountant’s Business Manual (AICPA); Valuing Professional Practices and Licenses (Aspen Publishers); Valuation Strategies; Business Appraisal Practice; and, NACVA QuickRead. In addition to his contributions as an author, Mr. Zigra has served as faculty before professional and trade associations such as the American Society of Appraisers (ASA); the National Association of Certified Valuators and Analysts (NACVA); Physician Hospitals of America (PHA); the Institute of Business Appraisers (IBA); the Healthcare Financial Management Association (HFMA); and, the CPA Leadership Institute.

Mr. Zigra holds a Master of Science in Health Administration (MHA) and a Master of Business Administration (MBA) from the University of Missouri at Columbia. He is a Fellow of the American College of Healthcare Executives (FACHE) and holds the Accredited Senior Appraiser (ASA) designation from the American Society of Appraisers, where he has served as President of the St. Louis Chapter, and is current Chair of the ASA Healthcare Special Interest Group (HSIG).

John R. Chwarzinski, MSF, MAE, is Senior Vice President of Health Capital Consultants (HCC). Mr. Chwarzinski’s areas of expertise include advanced statistical analysis, econometric modeling, as well as, economic and financial analysis. Mr. Chwarzinski is the co-author of peer-reviewed and industry articles published in Business Valuation Review and NACVA QuickRead, and he has spoken before the Virginia Medical Group Management Association (VMGMA) and the Midwest Accountable Care Organization Expo.

Mr. Chwarzinski holds a Master’s Degree in Economics from the University of Missouri – St. Louis, as well as, a Master’s Degree in Finance from the John M. Olin School of Business at Washington University in St. Louis. He is a member of the St. Louis Chapter of the American Society of Appraisers, as well as a candidate for the Accredited Senior Appraiser designation from the American Society of Appraisers.

Jessica L. Bailey-Wheaton, Esq., is Vice President and General Counsel of Health Capital Consultants (HCC), where she conducts project management and consulting services related to the impact of both federal and state regulations on healthcare exempt organization transactions and provides research services necessary to support certified opinions of value related to the Fair Market Value and Commercial Reasonableness of transactions related to healthcare enterprises, assets, and services. Ms. Bailey is a member of the Missouri and Illinois Bars and holds a J.D., with a concentration in Health Law, from Saint Louis University School of Law, where she served as Fall Managing Editor for the Journal of Health Law & Policy.

Kenneth J. Farris, Esq., is an Associate at Health Capital Consultants (HCC), where he provides research services necessary to support certified opinions of value related to the Fair Market Value and Commercial Reasonableness of transactions related to healthcare enterprises, assets, and services, and tracks impact of federal and state regulations on healthcare exempt organization transactions. Mr. Farris is a member of the Missouri Bar and holds a J.D. from Saint Louis University School of Law, where he served as the 2014-2015 Footnotes Managing Editor for the Journal of Health Law & Policy.